Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity

Oncogene

Volumn 22, Issue 52, 2003, Pages 8441-8447

  Del Bufalo, Donatella ^a   Trisciuoglio, Daniela ^a   Scarsella, Marco ^a   Zangemeister Wittke, Uwe ^b   Zupi, Gabriella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Angiogenesis; Antisense oligonucleotides; bcl 2; Melanoma; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; RNA STABILITY; TUMOR CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; BCL-X PROTEIN; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0348014548     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206999     Document Type: Article

References (46)

1. Bergers G, Javaherian K, Folkmam J and Hanahan D. (1999). Science, 284, 808-812.
2. Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G and Del Bufalo D. (2000). FASEB J., 14, 652-660.
3. Biroccio A, Del Bufalo D, Fanciulli M, Bruno T, Zupi G and Floridi A. (1999). Int. J. Cancer, 82, 125-130.
4. Boehm T, Folkman J, Browder T and O'Reilly MS. (1997). Nature, 390, 404-407.
5. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G and Cheresh DA. (1994). Cell, 79, 1157-1164.
6. Cristofanilli M, Charnsangavej C and Hortobagyi GN. (2002). Nat. Rev. Drug Discov., 1, 415-426.
7. Del Bufalo D, Biroccio A, Trisciuoglio D, Bruno T, Floridi A, Aquino A and Zupi G. (2002a). Eur. J. Cancer, 38, 2455-2462.
8. Del Bufalo D, Biroccio A, Leonetti C and Zupi G. (1997). FASEB J., 11, 947-953.
9. Del Bufalo D, Biroccio A, Soddu S, Laudonio N, D'Angelo C, Sacchi A and Zupi G. (1996). J. Clin. Invest., 98, 1165-1173.
10. Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosano L, Trisciuoglio D, Spinella F and Bagnato A. (2002b). Mol. Pharmacol., 61, 524-532.
11. Del Bufalo D, Trisciuoglio D, Biroccio A, Marcocci L, Buglioli S, Candiloro A, Scarsella M, Leonetti C and Zupi G. (2001). J. Cell. Biochem., 83, 473-483.
12. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL. (2001). N. Engl. J. Med., 344, 1031-1037.
13. Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles-Gerte E, McDonnell T and D'Amato R. (2001). J. Natl. Cancer Inst., 93, 208-213.
14. Folkman J. (1986). Cancer Res., 46, 467-473.
15. Folkman J. (2000). J. Natl. Cancer Inst., 92, 94-95.
16. Folkman J. (2002). Semin. Oncol., 29 (6 Suppl. 16), 15-18.
17. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP and McMahon G. (1999). Cancer Res., 59, 99-106.
18. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA and Zangemeister-Wittke U. (2001). J. Natl. Cancer Inst., 93, 463-471.
19. Hanahan D and Folkman J. (1996). Cell, 86, 353-364.
20. Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G and Del Bufalo D. (2002). FASEB J., 16, 1453-1455.
21. Jain RK. (2002). Semin. Oncol., 29 (6 Suppl. 16), 3-9.
22. Jansen B, Wacheck V, Heere-Ress, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K and Pehamberger H. (2000). Lancet, 356, 1728-1733.
23. Kinoshita M, Johnson DL, Shatney CH, Lee YL and Mochizuki H. (2001). Int. J. Cancer, 91, 322-326.
24. Klagsbrun M and Moses MA. (1999). Chem. Biol., 6, R217-R224.
25. Koty PP, Tyurina YY, Tyurin VA, Li SX and Kagan VE. (2002). Mol. Cell. Biochem., 234-235, 125-133.
26. McCarthy M. (2001). Lancet, 357, 1593.
27. Millauer B, Shwver LK, Plate KH, Risau W and Ullrich A. (1994). Nature, 367, 576-579.
28. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW and Pizzo SV. (1999). Proc. Natl. Acad. Sci. USA, 96, 2811-2816.
29. Moses MA. (1997). Stem Cells, 15, 180-189.
30. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS and Sukhatme VP. (1995). Nature, 375, 577-581.
31. Nam NH and Parang K. (2003). Curr. Drug Targets, 4, 159-179.
32. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Stricter RM and Polverini PJ. (2001). Cancer Res., 61, 2183-2188.
33. Nor JE, Christensen J, Mooney DJ and Polverini PJ. (1999). Am. J. Pathol., 154, 375-384.
34. Olie RA, Hafner C, Kuttel R, Sigrist B, Willers J, Dummer R, Hall J, Stahel RA and Zangemeister-Wittke U. (2002a). J. Invest. Dermatol., 118, 505-512.
35. Olie RA, Hall J, Natt F, Stahel RA and Zangemeister-Witthe U. (2002b). Biochim. Biophys. Acta, 1576, 101-109.
36. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J. (1997). Cell, 88, 277-285.
37. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M and Ferrara N. (1997). Cancer Res., 57, 4593-4599.
38. Rak J, Yu JL, Kerbel RS and Coomber BL. (2002). Cancer Res., 62, 1931-1934.
39. Ruoslaty E. (2002). Nat. Rev. Cancer, 2, 83-90.
40. Schechner JS, Nath AK, Zheng L, Kluger MS, Hughes CC, Sierra-Honigmann MR, Lorber MI, Tellides G, Kashgarian M, Bothwell AL and Pober JS. (2000). Proc. Natl. Acad. Sci. USA, 97, 9191-9196.
41. Simoes-Wust AP, Schurpf T, Hall J, Stahel RA and Zangemeister-Witthe U. (2002). Breast Cancer Res. Treat., 76, 157-166.
42. Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR and Ciardiello F. (2001). Clin. Cancer Res., 7, 2537-2544.
43. Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U and Ciardiello F. (2003). Clin. Cancer Res., 9, 866-871.
44. Wang JH, Wu QD, Bouchier-Hayes D and Redmond HP. (2002). Cancer, 94, 2745-2755.
45. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F and Cotter FE. (2000). J. Clin. Oncol., 18, 1812-1823.
46. Zangemeister-Wittke U, Leech S-H, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH, Natt F, Haner R, Martin P, Hall J, Nalin CM and Stahel RA. (2000). Clin. Cancer Res., 6, 2547-2555.